1-2 of 2
Melanie Davis
Close
Sort by
Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Jennifer A. Woyach, MD, Daphne Guinn, PhD, Amy S. Ruppert, MAS, James S. Blachly, MD, Arletta Lozanski, MS, Nyla A. Heerema, PhD, Weiqiang Zhao, MD PhD, Joshua Coleman, MD, Daniel Jones, Lynne V. Abruzzo, MD PhD, Amber Gordon, MLS, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Melanie Davis, PhD, Tzyy-Jye Doong, PhD, Fan Ny, CNP, Margaret S. Lucas, PA-C, Weihong Chase, CNP, Jeffrey Jones, MD MPH, Joseph M. Flynn, DO, MPH, Kami J. Maddocks, MD, Samantha Jaglowski, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Kristie Blum, MD, Michael R. Grever, MD, Gerard Lozanski, MD, John C. Byrd, MD, Amy J. Johnson, PhD
Journal: Blood
Blood (2016) 128 (22): 55.
https://doi.org/10.1182/blood.V128.22.55.55
Published: 2016
Journal Articles

Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab.

Farrukh Awan, MD, MS, Neil E. Kay, Melanie Davis, Wenting Wu, Nelson Leung, Diane F. Jelinek, Renee Tschumper, Charla Secreto, Thomas S. Lin, Michael R Grever, MD, Tait Shanafelt, MD, Clive S. Zent, Timothy G. Call, Nyla A. Heerema, PhD, Gerard Lozanski, John C. Byrd, MD, David Lucas, PhD
Journal: Blood
Blood (2008) 112 (11): 2105.
https://doi.org/10.1182/blood.V112.11.2105.2105
Published: 2008